NeoGenomics Secures Legal Victory as Natera Ends Patent Challenge, Clears Path for RaDaR ST Market Entry

NeoGenomics achieved a decisive win in its ongoing patent dispute after competitor Natera chose to discontinue its appellate proceedings, allowing the oncology diagnostics firm to move forward with confidence on its product roadmap. The decision means the August 2025 verdict from the Middle District of North Carolina—which ruled in NeoGenomics’ favor—will remain in effect without further legal challenges.

Patent Ruling Upholds NeoGenomics’ Position

The North Carolina District Court had previously determined that Natera’s patent claims lacked eligibility for patent protection, effectively invalidating both of the contested patents. The court’s summary judgment against Natera and the subsequent dismissal of claims with prejudice represent a comprehensive legal victory for NeoGenomics. By withdrawing its appeal, Natera has essentially conceded the litigation, eliminating the possibility of a reversal on appeal.

Clear Timeline for RaDaR ST Clinical Launch

With legal uncertainties removed, NeoGenomics is now positioned to execute a complete clinical rollout of its RaDaR ST molecular residual disease assay during the first quarter of 2026. According to Tony Zook, Chief Executive Officer, the company can now concentrate resources on this critical market introduction without the distraction of ongoing litigation.

“This resolution gives us the bandwidth to concentrate entirely on bringing RaDaR ST to market effectively,” Zook stated. “Though we remained confident throughout this process, ending the dispute accelerates our ability to focus on execution.”

About the Diagnostic Solution

RaDaR ST represents NeoGenomics’ molecular residual disease testing platform, designed to provide oncologists and hospital systems with precision diagnostic capabilities. The assay fits within NeoGenomics’ comprehensive oncology testing portfolio, which serves academic medical centers, pathology departments, and biopharmaceutical organizations across the United States and internationally.

Company Overview

NeoGenomics operates as a specialized cancer diagnostics provider with a network of CAP-accredited and CLIA-certified laboratory facilities. The organization maintains processing capabilities throughout the United States, with additional operations at its Cambridge, United Kingdom facility. The company’s headquarters are located in Fort Myers, Florida, and its stock trades on the NASDAQ under the ticker NEO.

The resolution of this patent litigation removes a significant regulatory and legal overhang for NeoGenomics, allowing investors and stakeholders to focus on the commercial potential of RaDaR ST as it approaches its anticipated debut in early 2026.